Nexalin Technology, Inc.

Nexalin designs and creates bioelectronic neurostimulation medical devices designed to address mental health conditions including anxiety, depression, and insomnia without pharmaceutical drugs or psychotherapy. Its core technology utilizes non-invasive electrical waveforms emitted through patient headsets and clinical systems. Offerings include its original Generation 1 cranial electrotherapy stimulation unit, alongside its advanced Generation 2 SYNC clinical console and Generation 3 HALO at-home headset systems. The company also supplies single-use radio-frequency identification electrodes, patient cables, and related licensing services. Customers comprise healthcare providers and licensed medical professionals who administer treatments in clinics or prescribe devices for home use via virtual clinic platforms.

Management and operating facilities are located at the company's headquarters in Houston, Texas. Beyond its domestic presence, the company maintains international regulatory approvals and operations across several jurisdictions. Its Generation 2 medical device holds regulatory clearance in Oman and Brazil, and approval in China through the National Medical Products Administration. Furthermore, clinical trials, marketing, and distribution throughout China and neighboring territories are conducted through a Hong Kong-registered joint venture, supported by a wholly foreign-owned enterprise office in the People's Republic of China.

Summary of the business section of Nexalin Technology's latest annual report, written by StockData.

“As of December 31, 2025, we had 8 full-time employees, our CMO is a consultant and we utilize varying levels of other consultants.”